Estados Unidos · Plataformas y datos · Morningstar

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

Publicado por Morningstar · Estados Unidos hace 1 d

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired Neurotech Pharmaceuticals, Inc., a company…

Leer el artículo completo en Morningstar Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.morningstar.com)

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

También te puede interesar

We have a $300,000 mortgage with a 2.75% interest rate. I want to pay it off. My husband says I’m crazy. Who’s right?

Volatus Aerospace Inc. (FLT.TO) - What Are Brokerages Saying About This Stock?

General Motors' Q3 Sales Slipped. Its Profits Soared. Here Are 3 Takeaways Investors Must Note.

Lam Research earnings beat by $0.02, revenue topped estimates

Goldman Sachs, JPMorgan and Morgan Stanley are dominating the AI stock boom. Here's their edge

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

Compartir

También te puede interesar

We have a $300,000 mortgage with a 2.75% interest rate. I want to pay it off. My husband says I’m crazy. Who’s right?

Volatus Aerospace Inc. (FLT.TO) - What Are Brokerages Saying About This Stock?

General Motors' Q3 Sales Slipped. Its Profits Soared. Here Are 3 Takeaways Investors Must Note.

Lam Research earnings beat by $0.02, revenue topped estimates

Goldman Sachs, JPMorgan and Morgan Stanley are dominating the AI stock boom. Here's their edge

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030